News | February 03, 2022
Caplin Point Q3FY22 PAT at Rs 74.95 cr.
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Mental health issues are a cause for concern and in a conservative society like India. Thomas C Thottathil spoke to Krishna Veer Singh, Co-Founder and CEO of Lissun, a young start-up working in the space of mental health
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Subscribe To Our Newsletter & Stay Updated
